The genetic polymorphisms of cathepsin S were associated with metabolic disorders in a Chinese Han population

Related Experiment Video

Updated: May 10, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Zejin Ou1, Guanghai Wang, Qiang Li

  • 1Department of Occupational Health and Occupational Medicine, School of Public Health and Tropical Medicine, Southern Medical University, Guangzhou, China.

Gene
|June 11, 2013
PubMed

Insights

Genetic variations in Cathepsin S (CTSS) are linked to metabolic disorders like obesity and high cholesterol in the Chinese Han population. These findings offer insights into the genetic basis of metabolic diseases.

Area of Science:

  • Genetics
  • Metabolic Disorders
  • Cardiovascular Disease

Background:

  • Cathepsin S (CTSS) is implicated in cardiovascular disease and metabolic syndrome.
  • Limited research exists on CTSS gene polymorphisms and metabolic disorders in Asian populations.
  • Understanding genetic associations is crucial for metabolic disease pathogenesis.

Purpose of the Study:

  • To investigate the association between CTSS gene polymorphisms and metabolic disorders.
  • To analyze these associations in a Chinese Han population cohort.

Main Methods:

  • A cohort of 1160 Chinese Han participants was studied.
  • Genotyping was performed using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP).
  • Statistical analyses were conducted to assess genotype-phenotype correlations and risks.

Main Results:

  • CTSS polymorphism rs16827671 associated with Body Mass Index (BMI) and serum total cholesterol.
  • Specific genotypes (CT of rs16827671, AG of rs11576175) and haplotypes (TA, CA) showed significant associations with hypercholesterolemia, hypertriglyceridemia, and borderline hypercholesterolemia.
  • Individuals with CT genotype for rs16827671 had increased hypercholesterolemia risk; AG genotype for rs11576175 showed reduced risks for hypertriglyceridemia and borderline hypercholesterolemia.

Conclusions:

  • Genetic polymorphisms in the CTSS gene are significantly associated with metabolic disorders in the Chinese Han population.
  • These findings contribute to understanding the genetic underpinnings of metabolic disease development.
  • Further research can explore CTSS's role in personalized medicine for metabolic health.

Keywords:
Association studyBMICICTSSDyslipidemiaECMGWASHDLHWEHardy–Weinberg equilibriumNCEP-ATP IIINational Cholesterol Education Program Adult Treatment Panel IIIORObesityPCR-RFLPTCTGbody mass indexcathepsin Sconfidence intervalextracellular matrixgenome-wide association studyhigh-density lipoproteinodds ratiopolymerase chain reaction-restriction fragment length polymorphismtotal cholesteroltriglyceride

More Related Videos

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...